Imagin Medical Inc. (IME:CSE; IMEXF:OTCQB) announced in a news release it completed the first step of the functional system stage in the development of its new medical technology, the i/Blue Imaging System. The company aims to get blue light cystoscopy into the mainstream standard of care for bladder cancer.
Both parts of the system's functional unit, the control console and the dual-camera hand piece, designed to operate in tandem, are working as expected in providing simultaneous high-resolution images in blue and white light modes. The functional unit is now 30% smaller than the prototype after Imagin optimized it, not only for size, but also performance and cost.
"We are excited to see the real promise of Imagin's groundbreaking technology start to emerge and believe that it will drive significant value for our shareholders as we progress," President and CEO Jim Hutchens said in the release.
To complete the entire functional system phase of development, Imagin must build additional units with enhanced software, verify them for various functions, including electrical safety, reprocessing and sterilization, and finish packaging and shipping simulations. The company is currently holding focus groups with urologists for feedback on how best to optimize the software user interface and meet specific functionality needs. Imagin aims to have these tasks done by mid-year.
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Imagin Medical. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Imagin Medical, a company mentioned in this article.
